Fennec Pharmaceuticals Inc. (FENC)
Nasdaq: FENC · Biological Products, (No Diagnostic Substances) · Research Triangle Park, NC · filing with the SEC since 2002
Who owns Fennec Pharmaceuticals Inc.
As filed with the SECHolders of 5% or more
4
Rosalind Advisors, Inc. holds 9.6% of Common Shares, as its SCHEDULE 13G/A filed Aug 13, 2026 says.
Directors and officers
10
report now, of 12 people on the record since 2007. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Rosalind Advisors, Inc.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Shares · 8.8% in May 14, 2026
Kam Lawrence
SCHEDULE 13G/A · filed Feb 17, 2026 · Common stock, no par value (the "Shares")
Orin Hirschman
SCHEDULE 13G/A · filed Oct 19, 2026 · Common Shares, no par value · 5.7% in Apr 28, 2026
Solas Capital Management, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Shares, no par value · 7.2% in May 15, 2026
DG Capital Management, LLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Shares · reported falling below 5%
Southpoint Master Fund, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Shares, no par value · reported falling below 5%, from 8% in Jan 14, 2026
What FENC reports owning in othersstakes of 5% or more, and other ties
Fennec Pharmaceuticals Inc. reports no stake in another company in the record.
Insider tradesForm 4
15sales
0purchases
14sales on a scheduled plan
5people selling
$2.2Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 2, 2025 to Nov 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 29 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Southpoint Capital Advisors LP | 10% owner | 1 | $7.5M | 0 | 0 | $0 |
| Southpoint Gp, LLC | 10% owner | 2 | $2.0M | 0 | 0 | $0 |
| Raykov Rosty | CHIEF EXECUTIVE OFFICER | 11 | $900,000 | 11 | 0 | $0 |
| Andrade Robert | CHIEF FINANCIAL OFFICER | 1 | $900,000 | 1 | 0 | $0 |
| Brughera Marco Maria | director | 1 | $200,000 | 1 | 0 | $0 |
| Southpoint Capital Advisors LLC | 10% owner | 1 | $200,000 | 0 | 0 | $0 |
| Sayad Pierre Sargis | Chief Medical Officer | 1 | $100,000 | 0 | 0 | $0 |
| Rallis Chris A | director | 1 | $100,000 | 1 | 0 | $0 |